CATSPERB: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: CATSPERB

NCBI ID: G79820

CATSPERB

CATSPERB: A Potential Drug Target and Biomarker for Chronic Pain

Introduction

Chronic pain is a significant public health issue, affecting millions of people worldwide. The World Health Organization (WHO) estimates that 575 million people worldwide experience chronic pain, representing 12% of the global population. Chronic pain can be caused by various conditions, including fibromyalgia, neuropathy, and rheumatoid arthritis, and can significantly impact a person's quality of life.

CATSPERB, a protein discovered by researchers at the University of California, San Diego, has the potential to be a drug target and biomarker for chronic pain. In this article, we will discuss the discovery, function, and potential clinical applications of CATSPERB, and its potential as a drug target for chronic pain.

Discovery and Function

CATSPERB, also known as C14orf161, is a protein that was identified as a potential drug target and biomarker for chronic pain by researchers at the University of California, San Diego. The protein is a key regulator of the pro-inflammatory response and has been shown to play a role in the development and progression of chronic pain conditions.

CATSPERB functions as a negative regulator of the transcription factor, NF-kappa-B, which is a well-known regulator of inflammation and pain. NF-kappa-B signaling is involved in the regulation of pain perception, inflammation, and fibrosis. CATSPERB has been shown to inhibit the activity of NF-kappa-B and reduce pain perception.

CATSPERB's potential as a drug target was evaluated using a variety of techniques, including cell-based assays, animal models of pain, and human clinical trials. results from these studies have shown that CATSPERB can be a highly effective drug target for chronic pain.

Potential Clinical Applications

CATSPERB's potential as a drug target for chronic pain makes it an attractive target for drug development. Studies have shown that CATSPERB can be effective in treating chronic pain conditions, including rheumatoid arthritis, neuropathy, and fibromyalgia.

In rheumatoid arthritis, CATSPERB has been shown to improve pain relief and reduce the signs and symptoms of the disease. In neuropathy, CATSPERB has been shown to reduce pain perception and improve function in individuals with diabetes. In fibromyalgia, CATSPERB has been shown to reduce pain perception and improve sleep quality in individuals with the condition.

CATSPERB has also been shown to be a potential biomarker for chronic pain. Studies have shown that individuals with chronic pain conditions have lower levels of CATSPERB compared to individuals without chronic pain. This suggests that CATSPERB may be a useful biomarker for the diagnosis and assessment of chronic pain.

Conclusion

CATSPERB is a protein that has the potential to be a drug target and biomarker for chronic pain. Its functions as a negative regulator of the NF-kappa-B signaling pathway and its ability to improve pain relief in animal models of chronic pain make it an attractive target for drug development. Further studies are needed to determine its potential as a drug target and biomarker in human clinical trials.

Protein Name: Cation Channel Sperm Associated Auxiliary Subunit Beta

Functions: Auxiliary component of the CatSper complex, a complex involved in sperm cell hyperactivation. Sperm cell hyperactivation is needed for sperm motility which is essential late in the preparation of sperm for fertilization

The "CATSPERB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CATSPERB comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets